Review Article | Published:

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Abstract

Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy over the past decade. The indications for these agents continue to expand across malignancies and disease settings, thus reshaping many of the previous standard-of-care approaches and bringing new hope to patients. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), which are often distinctly different from the classical chemotherapy-related toxicities. Owing to the growing use of ICIs in oncology, clinicians will increasingly be confronted with common but also rare irAEs; hence, awareness needs to be raised regarding the clinical presentation, diagnosis and management of these toxicities. In this Review, we provide an overview of the various types of irAEs that have emerged to date. We discuss the epidemiology of these events and their kinetics, risk factors, subtypes and pathophysiology, as well as new insights regarding screening and surveillance strategies. We also highlight the most important aspects of the management of irAEs.

Key points

  • The frequency of immune-related adverse events (irAEs) is dependent on the agents used, exposure time and the administered dose but also on the patient’s intrinsic risk factors; conversely, the timing of appearance is often dictated by the affected organ systems.

  • High-risk patients receiving immune-checkpoint inhibitors (ICIs) should be regularly monitored for treatment-related complications by specialized multidisciplinary teams, ideally using a personalized surveillance strategy.

  • The application of formal contraindications to the use of ICIs among patients with a high risk of irAEs is not supported by well-founded scientific evidence.

  • In patients with severe and/or steroid-refractory irAEs, a biopsy sample should be obtained and investigated for infiltrating immune cells in order to enable the selection of novel biological agents targeting key inflammatory mediators.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Calvo, C. R., Amsen, D. & Kruisbeek, A. M. Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70. J. Exp. Med. 186, 1645–1653 (1997).

  2. 2.

    Carreno, B. M. et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J. Immunol. 165, 1352–1356 (2000).

  3. 3.

    Takahashi, T. et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303–310 (2000).

  4. 4.

    Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).

  5. 5.

    Okazaki, T. & Honjo, T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27, 195–201 (2006).

  6. 6.

    Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).

  7. 7.

    Schadendorf, D. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889–1894 (2015).

  8. 8.

    Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

  9. 9.

    Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).

  10. 10.

    Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).

  11. 11.

    Antonia, S. J. et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17, 883–895 (2016).

  12. 12.

    Hellmann, M. D. et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 18, 31–41 (2017).

  13. 13.

    Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).

  14. 14.

    Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721–1728 (2018).

  15. 15.

    Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26, 3552–3559 (2008).

  16. 16.

    Gooley, T. A. et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 363, 2091–2101 (2010).

  17. 17.

    Eggermont, A. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).

  18. 18.

    Weber, J. S., Kahler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691–2697 (2012).

  19. 19.

    Cuzzubbo, S. et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur. J. Cancer 73, 1–8 (2017).

  20. 20.

    Gelao, L., Criscitiello, C., Esposito, A., Goldhirsch, A. & Curigliano, G. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an “innocent bystander”. Toxins (Basel) 6, (914–933 (2014).

  21. 21.

    Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).

  22. 22.

    Luis Paz-Ares, M. D. et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).

  23. 23.

    Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006–2017 (2015).

  24. 24.

    Ornstein, M. C. & Garcia, J. A. Toxicity of checkpoint inhibition in advanced RCC: a systematic review. Kidney Cancer 1, 133–141 (2017).

  25. 25.

    Hammers, H. J. et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J. Clin. Oncol. 35, 3851–3858 (2017).

  26. 26.

    Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L. & Hansen, A. R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol. 28, 2377–2385 (2017).

  27. 27.

    El Osta, B., Hu, F., Sadek, R., Chintalapally, R. & Tang, S. C. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit. Rev. Oncol. Hematol. 119, 1–12 (2017).

  28. 28.

    Khunger, M. et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 152, 271–281 (2017).

  29. 29.

    Pillai, R. N. et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer 124, 271–277 (2018).

  30. 30.

    Xu, C. et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363, k4226 (2018).

  31. 31.

    Kelly, K. et al. Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer 124, 2010–2017 (2018).

  32. 32.

    Naidoo, J. et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J. Clin. Oncol. 35, 709–717 (2017).

  33. 33.

    Yamaguchi, T. et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis. Lung Cancer 125, 212–217 (2018).

  34. 34.

    Kim, J. H., Kim, H. S. & Kim, B. J. Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Oncotarget 8, 93149–93155 (2017).

  35. 35.

    Haratani, K. et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 4, 374–378 (2018).

  36. 36.

    Villadolid, J. & Amin, A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 4, 560–575 (2015).

  37. 37.

    Belum, V. R. et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur. J. Cancer 60, 12–25 (2016).

  38. 38.

    Teulings, H. E. et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J. Clin. Oncol. 33, 773–781 (2015).

  39. 39.

    Min Lee, C. K. et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study. J. Am. Acad. Dermatol. 79, 1047–1052 (2018).

  40. 40.

    Trinidad, C. et al. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. J. Cutan. Pathol. 45, 504–507 (2018).

  41. 41.

    Lacouture, M. E. et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J. Am. Acad. Dermatol. 71, 161–169 (2014).

  42. 42.

    Weber, J. S. et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119, 1675–1682 (2013).

  43. 43.

    Voudouri, D. et al. Anti-PD1/PDL1 induced psoriasis. Curr. Probl. Cancer 41, 407–412 (2017).

  44. 44.

    Shao, K., McGettigan, S., Elenitsas, R. & Chu, E. Y. Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD-1 therapy. J. Cutan. Pathol. 45, 74–77 (2018).

  45. 45.

    Hwang, S. J. et al. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res. 26, 413–416 (2016).

  46. 46.

    Sibaud, V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am. J. Clin. Dermatol. 19, 345–361 (2018).

  47. 47.

    Dougan, M. Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front. Immunol. 8, 1547 (2017).

  48. 48.

    Messmer, M. et al. Ipilimumab-induced enteritis without colitis: a new challenge. Case Rep. Oncol. 9, 705–713 (2016).

  49. 49.

    Ibraheim, H. et al. Microscopic colonic inflammation in immune check point inhibitor-induced diarrhoea/colitis [abstract PWE-025]. Gut 67 (Suppl. 1), A80 (2018).

  50. 50.

    Abu-Sbeih, H. et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J. Immunother. Cancer 6, 95 (2018).

  51. 51.

    Johnson, D. H. et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J. Immunother. Cancer 6, 103 (2018).

  52. 52.

    Read, S., Malmstrom, V. & Powrie, F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295–302 (2000).

  53. 53.

    Zeissig, S. et al. Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4. Gut 64, 1889–1897 (2015).

  54. 54.

    Pitt, J. M. et al. Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. Oncoimmunology 6, e1132137 (2017).

  55. 55.

    Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).

  56. 56.

    Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28, 1368–1379 (2017).

  57. 57.

    Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).

  58. 58.

    Wang, Y. et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 24, 1804–1808 (2018).

  59. 59.

    Tarhini, A. A. et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 3, 39 (2015).

  60. 60.

    Kanai, T. et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J. Immunol. 171, 4156–4163 (2003).

  61. 61.

    Reynoso, E. D. et al. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J. Immunol. 182, 2102–2112 (2009).

  62. 62.

    Chuzi, S. et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag. Res. 9, 207–213 (2017).

  63. 63.

    Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N. H. & Hodi, F. S. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2, 1607–1616 (2016).

  64. 64.

    Koelzer, V. H. et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J. Immunother. Cancer 4, 13 (2016).

  65. 65.

    Leroy, V. et al. Pembrolizumab-induced pneumonitis. ERJ Open Res. https://doi.org/10.1183/23120541.00081-2016 (2017).

  66. 66.

    Montaudie, H., Pradelli, J., Passeron, T., Lacour, J. P. & Leroy, S. Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br. J. Dermatol. 176, 1060–1063 (2017).

  67. 67.

    Cukier, P., Santini, F. C., Scaranti, M. & Hoff, A. O. Endocrine side effects of cancer immunotherapy. Endocr. Relat. Cancer 24, T331–T347 (2017).

  68. 68.

    Faje, A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19, 82–92 (2016).

  69. 69.

    Blansfield, J. A. et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. 28, 593–598 (2005).

  70. 70.

    Corsello, S. M. et al. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 98, 1361–1375 (2013).

  71. 71.

    Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl Med. 6, 230ra245 (2014).

  72. 72.

    Caturegli, P. et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am. J. Pathol. 186, 3225–3235 (2016).

  73. 73.

    Ribas, A. et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616–622 (2013).

  74. 74.

    Okano, Y. et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr. J. 63, 905–912 (2016).

  75. 75.

    Gonzalez-Rodriguez, E. & Rodriguez-Abreu, D. & Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21, 804–816 (2016).

  76. 76.

    de Filette, J. et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J. Clin. Endocrinol. Metab. 101, 4431–4439 (2016).

  77. 77.

    Lee, H. et al. Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy. Cancer Immunol. Res. 5, 1133–1140 (2017).

  78. 78.

    Yamauchi, I. et al. Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid 27, 894–901 (2017).

  79. 79.

    Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).

  80. 80.

    Wang, W., Lie, P., Guo, M. & He, J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data. Int. J. Cancer 141, 1018–1028 (2017).

  81. 81.

    Suzman, D. L., Pelosof, L., Rosenberg, A. & Avigan, M. I. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 38, 976–987 (2018).

  82. 82.

    Karamchandani, D. M. & Chetty, R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective. J. Clin. Pathol. 71, 665–671 (2018).

  83. 83.

    Johncilla, M. et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am. J. Surg. Pathol. 39, 1075–1084 (2015).

  84. 84.

    Everett, J., Srivastava, A. & Misdraji, J. Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am. J. Surg. Pathol. 41, 134–137 (2017).

  85. 85.

    Mahmood, S. S. et al. Myocarditis in patients treated with immune checkpoint inhibitors. J. Am. Coll. Cardiol. 71, 1755–1764 (2018).

  86. 86.

    Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).

  87. 87.

    Moslehi, J. J., Salem, J. E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391, 933 (2018).

  88. 88.

    Heinzerling, L. et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J. Immunother. Cancer 4, 50 (2016).

  89. 89.

    Varricchi, G. et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2, e000247 (2017).

  90. 90.

    Matson, D. R., Accola, M. A., Rehrauer, W. M. & Corliss, R. F. Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab. J. Forensic Sci. 63, 954–957 (2017).

  91. 91.

    Touat, M., Talmasov, D., Ricard, D. & Psimaras, D. Neurological toxicities associated with immune-checkpoint inhibitors. Curr. Opin. Neurol. 30, 659–668 (2017).

  92. 92.

    Kao, J. C. et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 74, 1216–1222 (2017).

  93. 93.

    Astaras, C., de Micheli, R., Moura, B., Hundsberger, T. & Hottinger, A. F. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr. Neurol. Neurosci. Rep. 18, 3 (2018).

  94. 94.

    Ghosn, J. et al. A severe case of neuro-Sjogren’s syndrome induced by pembrolizumab. J. Immunother. Cancer 6, 110 (2018).

  95. 95.

    Williams, T. J. et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 73, 928–933 (2016).

  96. 96.

    Brown, M. P., Hissaria, P., Hsieh, A. H., Kneebone, C. & Vallat, W. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J. Neuroimmunol. 305, 16–18 (2017).

  97. 97.

    Papadopoulos, K. P. et al. Anti-Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 23, 118–120 (2018).

  98. 98.

    Chen, J. H., Lee, K. Y., Hu, C. J. & Chung, C. C. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore) 96, e9262 (2017).

  99. 99.

    Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378, 1789–1801 (2018).

  100. 100.

    Suzuki, S. et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89, 1127–1134 (2017).

  101. 101.

    Makarious et al. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur. J. Cancer 82, 128–136 (2017).

  102. 102.

    Huh, S. Y. et al. Emergence of myasthenia gravis with myositis in a patient treated with pembrolizumab for thymic cancer. J. Clin. Neurol. 14, 115–117 (2018).

  103. 103.

    Butt, S. & Bhaumik, S. Acute demyelinating polyneuropathy caused by nivolumab in a man with metastatic non-small cell lung cancer. J. Gerontol. Geriatr. Res. 5, 302 (2016).

  104. 104.

    Johnson, D. B. et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol. Res. 3, 464–469 (2015).

  105. 105.

    Yeh, O. L. & Francis, C. E. Ipilimumab-associated bilateral optic neuropathy. J. Neuroophthalmol 35, 144–147 (2015).

  106. 106.

    Altman, A. L., Golub, J. S., Pensak, M. L. & Samy, R. N. Bilateral facial palsy following ipilimumab infusion for melanoma. Otolaryngol. Head Neck Surg. 153, 894–895 (2015).

  107. 107.

    Voskens, C. J. et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLOS ONE 8, e53745 (2013).

  108. 108.

    Fukumoto, Y., Kuwahara, M., Kawai, S., Nakahama, K. & Kusunoki, S. Acute demyelinating polyneuropathy induced by nivolumab. J. Neurol. Neurosurg. Psychiatry 89, 435–437 (2018).

  109. 109.

    Abdel-Rahman, O. et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev. Anticancer Ther. 17, 387–394 (2017).

  110. 110.

    Caspi, R. R. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. Immunol. 8, 970–976 (2008).

  111. 111.

    Conrady, C. D. et al. Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch. Clin. Exp. Ophthalmol. 256, 187–191 (2018).

  112. 112.

    Read, R. W. et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am. J. Ophthalmol. 131, 599–606 (2001).

  113. 113.

    Caspi, R. R. A look at autoimmunity and inflammation in the eye. J. Clin. Invest. 120, 3073–3083 (2010).

  114. 114.

    Broekhuyse, R. M., Kuhlmann, E. D. & Winkens, H. J. Experimental autoimmune anterior uveitis (EAAU). III. Induction by immunization with purified uveal and skin melanins. Exp. Eye Res. 56, 575–583 (1993).

  115. 115.

    Chen, L. et al. Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. Ocul. Immunol. Inflamm. 17, 47–55 (2009).

  116. 116.

    Matsuo, T. & Yamasaki, O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin. Case Rep. 5, 694–700 (2017).

  117. 117.

    Tamura, T. et al. Vogt-Koyanagi-Harada syndrome induced by pembrolizumab in a patient with non-small-cell lung cancer. J. Thorac Oncol. 13, 1606–1607 (2018).

  118. 118.

    Crosson, J. N. et al. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J. Immunother. 38, 80–84 (2015).

  119. 119.

    Antoun, J., Titah, C. & Cochereau, I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr. Opin. Oncol. 28, 288–294 (2016).

  120. 120.

    Gonzales, J. A., Shantha, J. & Acharya, N. R. Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis. Am. J. Ophthalmol. Case Rep. 10, 117–118 (2018).

  121. 121.

    Pushkarevskaya, A., Neuberger, U., Dimitrakopoulou-Strauss, A., Enk, A. & Hassel, J. C. Severe ocular myositis after ipilimumab treatment for melanoma: a report of 2 cases. J. Immunother. 40, 282–285 (2017).

  122. 122.

    Campredon, P. et al. Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment. Eur. Thyroid J 7, 84–87 (2018).

  123. 123.

    Cappelli, L. C., Gutierrez, A. K., Bingham, C. O. 3rd & Shah, A. A. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. (Hoboken) 69, 1751–1763 (2017).

  124. 124.

    Goldstein, B. L., Gedmintas, L. & Todd, D. J. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol. 66, 768–769 (2014).

  125. 125.

    Vanoverbeke, L. & Sprangers, B. Management of checkpoint inhibitor-associated renal toxicities. Expert Rev. Qual. Life Cancer Care 2, 215–223 (2017).

  126. 126.

    Shirali, A. C., Perazella, M. A. & Gettinger, S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am. J. Kidney Dis. 68, 287–291 (2016).

  127. 127.

    Cortazar, F. B. et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 90, 638–647 (2016).

  128. 128.

    Izzedine, H. & Perazella, M. A. Anticancer drug-induced acute kidney injury. Kidney Int. Rep. 2, 504–514 (2017).

  129. 129.

    Kong, B. Y., Micklethwaite, K. P., Swaminathan, S., Kefford, R. F. & Carlino, M. S. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 26, 202–204 (2016).

  130. 130.

    King, J., de la Cruz, J. & Lutzky, J. Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP). J. Immunother. Cancer 5, 19 (2017).

  131. 131.

    Delyon, J., Mateus, C. & Lambert, T. Hemophilia A induced by ipilimumab. N. Engl. J. Med. 365, 1747–1748 (2011).

  132. 132.

    Shiuan, E. et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J. Immunother. Cancer 5, 8 (2017).

  133. 133.

    Thibult, M. L. et al. PD-1 is a novel regulator of human B cell activation. Int. Immunol. 25, 129–137 (2013).

  134. 134.

    Michot, J. M. et al. Immune-related bone marrow failure following anti-PD1 therapy. Eur. J. Cancer 80, 1–4 (2017).

  135. 135.

    Sadaat, M. & Jang, S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. J. Immunother. Cancer 6, 49 (2018).

  136. 136.

    Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, (Suppl. 4), iv119–iv142 (2017).

  137. 137.

    Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).

  138. 138.

    National Comprehensive Cancer Network. Management of immunotherapy-related toxicities. NCCN https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf (2018).

  139. 139.

    Martins, F. et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 20, e54–e64 (2019).

  140. 140.

    Horisberger, A. et al. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J. Immunother. Cancer 6, 156 (2018).

  141. 141.

    Johnson, D. B. et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234–240 (2016).

  142. 142.

    Menzies, A. M. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368–376 (2017).

  143. 143.

    Leonardi, G. C. et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J. Clin. Oncol. 36, 1905–1912 (2018).

  144. 144.

    Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A. & Suarez-Almazor, M. E. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann. Intern. Med. 169, 133–134 (2018).

  145. 145.

    Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).

  146. 146.

    Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2016).

  147. 147.

    Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).

  148. 148.

    Uemura, M. et al. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report. J. Hematol. Oncol. 9, 81 (2016).

  149. 149.

    Volkova, M. & Russell, R. 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr. Cardiol. Rev. 7, 214–220 (2011).

  150. 150.

    Callejo, A., Sedó-Cabezón, L., Juan, I. D. & Llorens, J. Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies. Toxics 3, 268–293 (2015).

  151. 151.

    Solans-Laque, R. et al. Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes. Lupus 13, 159–164 (2004).

  152. 152.

    Collins, L. K., Chapman, M. S., Carter, J. B. & Samie, F. H. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr. Probl. Cancer 41, 125–128 (2017).

  153. 153.

    Wang, P. F. et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front. Pharmacol. 8, 730 (2017).

  154. 154.

    Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M. E. & Schaeverbeke, T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 13, 211 (2015).

  155. 155.

    Spain, L. & Larkin, J. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert Opin. Biol. Ther. 16, 389–396 (2016).

  156. 156.

    Soularue, E. et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 67, 2056–2067 (2018).

  157. 157.

    Beck, K. E. et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24, 2283–2289 (2006).

  158. 158.

    Gupta, A., De Felice, K. M., Loftus, E. V. Jr & Khanna, S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment. Pharmacol. Ther. 42, 406–417 (2015).

  159. 159.

    Girotra, M. et al. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2, pky021 (2018).

  160. 160.

    Faje, A. T. et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J. Clin. Endocrinol. Metab. 99, 4078–4085 (2014).

  161. 161.

    Patel, N. S., Oury, A., Daniels, G. A., Bazhenova, L. & Patel, S. P. Incidence of thyroid function test abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment. Oncologist 23, 1236–1241 (2018).

  162. 162.

    De Martin, E. et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J. Hepatol. 68, 1181–1190 (2018).

  163. 163.

    Gauci, M. L. et al. Immune-related hepatitis with immunotherapy: are corticosteroids always needed? J. Hepatol. 69, 548–550 (2018).

  164. 164.

    Wanchoo, R. et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am. J. Nephrol. 45, 160–169 (2017).

  165. 165.

    Calabrese, C., Kirchner, E., Kontzias, K., Velcheti, V. & Calabrese, L. H. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open 3, e000412 (2017).

  166. 166.

    Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

  167. 167.

    Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).

  168. 168.

    Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).

  169. 169.

    Gulley, J. L. et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 18, 599–610 (2017).

  170. 170.

    Kaufman, H. L. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 17, 1374–1385 (2016).

  171. 171.

    Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265 (2017).

  172. 172.

    Garassino, M. C. et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 19, 521–536 (2018).

Download references

Acknowledgements

F.M. acknowledges the support of the Personalized Health and Related Technologies (PHRT) strategic focus area of the Swiss Federal Institutes of Technology (ETH) Domain and the Swiss Personalized Health Network (SPHN) initiative of the Swiss Academy of Medical Sciences (project no. 2017-407). The work of G.P.S. is partly supported by a 2016 Leenaards Foundation Fellowship for Academic Advancement in Clinical Medicine. The authors thank R. Guindon for his help in the conception of the figures.

Author information

F.M. and M.O. researched data for this manuscript. F.M., J.A.T. and M.O. discussed manuscript content. All authors wrote the manuscript. F.M., G.P.S. and M.O. edited and/or reviewed the manuscript before submission.

Correspondence to Michel Obeid.

Ethics declarations

Competing interests

S.P. has received education grants from and provided consultation, attended advisory boards and/or provided lectures for the following organizations: Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Eli Lilly, F. Hoffmann-La Roche, Janssen, Merck Serono, Merck Sharp and Dohme, Novartis, Pfizer, Regeneron and Takeda. All other authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Fig. 1: Kinetics of main irAEs.
Fig. 2: The spectrum of irAEs by affected organ or organs.